Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918877 | 1.00 | NOS1 (0.37) | NOS1NOS3NOS2DPP4LTA4H | |
| SCHEMBL2366734 | 0.84 | DPP4 (0.33) | NOS1NOS3NOS2DPP4SLC7A5 | |
| SCHEMBL3294154 | 0.82 | NOS1 (0.42) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL569252 | 0.82 | NOS1 (0.39) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL4240667 | 0.82 | LTA4H (0.35) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL2611904 | 0.81 | NOS1 (0.40) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL30904855 | 0.80 | NOS1 (0.34) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL8633236 | 0.80 | LTA4H (0.34) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL31145590 | 0.80 | NOS1 (0.34) | NOS1NOS3NOS2LTA4HSLC7A5 | |
| SCHEMBL186691 | 0.80 | NOS1 (0.38) | NOS1NOS3NOS2LTA4HSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138988-A1 | Spiropyrrolidine Derived Antiviral Agents | ENANTA PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12479854-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4376834-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043045-A | Novel spiropyrrolidine derived antiviral drugs | 英安塔制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023009187-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-7871998-B2 | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| EP-1699759-B1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1699759-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061452-A1 | DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| CN-1582151-A | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia | ASTRAZENECA AB (SE) | 2005-02-16 | — | — | CN | disclosed |
| US-6610680-B1 | Administering as adjuncts in heart failure or as antithrombotic agents, treatment of obsessive-compulsive disorder, aggressive disorders, depression and anxiety | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-6521611-B2 | 2-(azetidin-2-on-1-yl) acetic acid derivatives; treatment of obsessive-compulsive disorder | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-0939632-A4 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | LILLY CO ELI (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | BRUNS ROBERT F (US) | 2002-04-25 | — | — | US | disclosed |
| US-6204260-B1 | 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES | ELI LILLY AND COMPANY | 2001-03-20 | — | — | US | disclosed |
| EP-0939632-A1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1997030707-A1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138988-A1 | Spiropyrrolidine Derived Antiviral Agents | ACE, ACE2, TMPRSS2 | NOS1 1994/4885NOS3 1722/4885NOS2 3055/4885 |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | NOS1 396/4885NOS3 1207/4885NOS2 917/4885 |
| US-12479854-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | NOS1 1501/4885NOS3 2215/4885NOS2 2151/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | NOS1 2918/4885NOS3 3768/4885NOS2 2946/4885 |
| US-20080064676-A1 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | NOS1 2918/4885NOS3 3768/4885NOS2 2946/4885 |
| US-20230122228-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | NOS1 1758/4885NOS3 2423/4885NOS2 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.